Dogwood Therapeutics, Inc.
DWTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001818844
No open-market purchases or sales by Dogwood Therapeutics, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $6.16M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Dogwood Therapeutics, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 15 | 17 | +2 |
| Shares | 1.10M | 1.14M | +39.8K (+3.6%) |
| Value | $4.91M | $4.80M | −$105.0K (−2.1%) |
New holders (5)
Institutions that held Dogwood Therapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Koshinski Asset Management, Inc. | 40,924 | $173.0K | 0.02% |
| Wiley Bros.-Aintree Capital, LLC | 11,000 | $47.0K | 0.03% |
| State Street Corp | 10,628 | $45.0K | 0.00% |
| Urban Wealth Management, LLC | 2,455 | $10.0K | 0.03% |
| Tevis Investment Management | 75 | $0 | 0.00% |
Sold out (3)
Institutions that held Dogwood Therapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Two Sigma Advisers, LP | 14,400 | $65.0K |
| UBS Group AG | 14,137 | $63.0K |
| Wolff Wiese Magana LLC | 52 | $0 |